An International Multicenter, Retrospective Cohort Study of 203 Patients with Pediatric Androgenetic Alopecia.

IF 12.8 1区医学 Q1 DERMATOLOGY

Journal of the American Academy of Dermatology Pub Date : 2025-02-05 DOI:10.1016/j.jaad.2025.02.002

Tyan Shin Lee, Mara O'Connor, Leslie Castelo-Soccio, Dawn Eichenfield, Danny Lee, Amy S Paller, Manuel Valdebran, Jenna Vroman, Angela Yang, Grace L Lee, Megan Craddock, Cathryn Sibbald

{"title":"An International Multicenter, Retrospective Cohort Study of 203 Patients with Pediatric Androgenetic Alopecia.","authors":"Tyan Shin Lee, Mara O'Connor, Leslie Castelo-Soccio, Dawn Eichenfield, Danny Lee, Amy S Paller, Manuel Valdebran, Jenna Vroman, Angela Yang, Grace L Lee, Megan Craddock, Cathryn Sibbald","doi":"10.1016/j.jaad.2025.02.002","DOIUrl":null,"url":null,"abstract":"Background: Androgenetic alopecia (AGA) is a nonscarring alopecia with increasing prevalence in pediatric populations. Published data in pediatrics is limited.Objective: To perform a multi-center review of pediatric patients with AGA to study clinical presentation, comorbidities, and treatment recommendations.Methods: A retrospective review of patients presenting with AGA at age <18 years with adequate documentation for data extraction.Results: In total, 203 patients were included. The mean age of AGA onset was 12.9 ± 2.7 years, and at diagnosis was 14.5 ± 2.1 years. Prepubertal onset occurred in 17 patients, 70.6% female. The majority had a family history of AGA. Of 145 patients with anthropometric data, 24.1% were obese (>95th percentile) and 24.8% overweight (85-95th percentile). Treatments at diagnosis included topical minoxidil in 76.5% and systemic minoxidil in 2.9%, spironolactone in 5.7% of females, and 5-alpha reductase inhibitors in 1.7% of males. Side effects were rare.Limitations: Data was limited to recorded information.Conclusion: AGA can occur in prepubertal patients. Potential risk factors for pediatric AGA include obesity and family history. Minoxidil has clinical benefit and is well tolerated in this population. Further prospective studies are recommended to confirm these findings and gather more evidence for treatments.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaad.2025.02.002","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Androgenetic alopecia (AGA) is a nonscarring alopecia with increasing prevalence in pediatric populations. Published data in pediatrics is limited.

Objective: To perform a multi-center review of pediatric patients with AGA to study clinical presentation, comorbidities, and treatment recommendations.

Methods: A retrospective review of patients presenting with AGA at age <18 years with adequate documentation for data extraction.

Results: In total, 203 patients were included. The mean age of AGA onset was 12.9 ± 2.7 years, and at diagnosis was 14.5 ± 2.1 years. Prepubertal onset occurred in 17 patients, 70.6% female. The majority had a family history of AGA. Of 145 patients with anthropometric data, 24.1% were obese (>95^th percentile) and 24.8% overweight (85-95^th percentile). Treatments at diagnosis included topical minoxidil in 76.5% and systemic minoxidil in 2.9%, spironolactone in 5.7% of females, and 5-alpha reductase inhibitors in 1.7% of males. Side effects were rare.

Limitations: Data was limited to recorded information.

Conclusion: AGA can occur in prepubertal patients. Potential risk factors for pediatric AGA include obesity and family history. Minoxidil has clinical benefit and is well tolerated in this population. Further prospective studies are recommended to confirm these findings and gather more evidence for treatments.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Academy of Dermatology 医学-皮肤病学

CiteScore

8.60

自引率

5.80%

发文量

2023

审稿时长

49 days

期刊介绍： The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.